‘I’m a doctor and I took Mounjaro, there are things you need to know’
A UK-based doctor experienced significant physical and psychological changes while taking the weight-loss medication Mounjaro, ultimately leading him to temporarily discontinue use before restarting treatment under medical supervision. Dr. Sachin Khunti’s experience highlights the complex interplay between physiology and psychology when addressing obesity.
The Impact of Mounjaro on a Physician
Dr. Khunti, 33, began taking Mounjaro after determining he met the clinical criteria for obesity. Prior to starting the medication, he weighed just under 15 stone 4 pounds (approximately 96.4 kg) with a 38.5-inch waist. Within three months, he lost almost two stone, dropping to 13 stone 1 pound (approximately 82.1 kg) and reducing his waist size to 35 inches.
Beyond Weight Loss: Psychological Effects
While the physical changes were notable, Dr. Khunti reported the most surprising effect was a reduction in what he termed “food noise”—the constant internal thoughts about food. He also observed a decreased desire for alcohol while on the medication. Friends and family noticed changes in his appetite and mood.
However, these psychological effects were not sustained after he stopped taking Mounjaro. Within two months, his weight increased to 85.5kg and his waist returned to 36.3 inches, and the cravings returned, particularly during stressful situations or social events. This experience reinforced his belief that addressing the biological factors of obesity requires a long-term strategy.
Restarting Treatment and a Holistic Approach
Dr. Khunti has since resumed Mounjaro treatment at a 5mg dose under medical supervision, currently weighing approximately 83kg. He emphasizes that medication is most effective when combined with adequate protein intake, resistance training, sleep optimization, and structured physical activity. He also noted the importance of addressing the societal stigma surrounding obesity.
Dr. Khunti’s decision to begin taking Mounjaro was based on medical risk factors, including being a South Asian male with elevated LDL cholesterol and a family history of cardiometabolic disease. He consulted a regulated private provider before starting treatment.
Important Considerations and Cautions
Dr. Khunti cautions that Mounjaro and similar GLP-1-based therapies are not suitable for everyone. They should be avoided during pregnancy or breastfeeding and are contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), as well as those with certain gastrointestinal or endocrine conditions. Proper medical assessment, monitoring, and a thorough discussion of risks and benefits are essential.
Frequently Asked Questions
What was the most surprising change Dr. Khunti experienced while on Mounjaro?
Dr. Khunti was most surprised by the reduction in “food noise”—the constant background thoughts about food—and a decreased desire for alcohol.
How quickly did Dr. Khunti’s cravings return after stopping Mounjaro?
Dr. Khunti reported that his appetite signals and cravings returned quickly, within two months of stopping the medication, particularly during social events or periods of stress.
What does Dr. Khunti believe is essential for successful long-term weight management?
Dr. Khunti believes that medication should be part of a broader plan that includes adequate protein intake, resistance training, sleep optimization, and structured physical activity.
Given Dr. Khunti’s experience, how might a holistic approach to weight management, combining medication with lifestyle changes, improve long-term outcomes for individuals struggling with obesity?